[HTML][HTML] 阿法替尼一线治疗5 例晚期肺腺癌患者的不良反应分析及相关文献回顾
陶虹， 郭丽丽， 唐俊舫， 朱允中， 徐丽艳… - Chinese Journal of …, 2014 - ncbi.nlm.nih.gov
背景与目的阿法替尼是一种新型的低分子量人类表皮生长因子受体(human epidermal growth
factor receptor, HER) 家族抑制剂, 它属于第二代表皮生长因子受体-酪氨酸激酶抑制剂 …
factor receptor, HER) 家族抑制剂, 它属于第二代表皮生长因子受体-酪氨酸激酶抑制剂 …
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung …
Introduction The IPASS trial demonstrated superior progression free survival for Asian,
light/never smoking, advanced, pulmonary adenocarcinoma patients treated with first-line …
light/never smoking, advanced, pulmonary adenocarcinoma patients treated with first-line …
[HTML][HTML] Nrf2 在EGFR 基因突变肺腺癌中的表达及其与EGFR-TKIs 疗效间的相关性研究
朱翔， 梁莉， 柳晨， 尹文琤， 陈森… - Chinese Journal of Lung …, 2014 - ncbi.nlm.nih.gov
背景与目的表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine
kinase inhibitors, EGFR-TKIs) 是含有EGFR 基因敏感突变肺腺癌患者一线治疗首选药物 …
kinase inhibitors, EGFR-TKIs) 是含有EGFR 基因敏感突变肺腺癌患者一线治疗首选药物 …
The efficacy of single-agent epidermal growth factor receptor tyrosine kinase inhibitor therapy in biologically selected patients with non-small-cell lung cancer: a meta …
G Li, S Gao, Z Sheng, B Li - Chemotherapy, 2016 - karger.com
Objective: To determine the efficacy of first-generation single-agent epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in advanced non-small-cell lung …
receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in advanced non-small-cell lung …
Cell-Surface Receptors: EGFR-and VEGFR-Targeted Agents
J Aguilar-Company, I Ruiz-Camps - Infectious Complications in Biologic …, 2022 - Springer
This review aims to analyze, from an infectious disease perspective, the safety profile of
antineoplastic therapies targeting cell surface receptors and associated signaling pathways …
antineoplastic therapies targeting cell surface receptors and associated signaling pathways …
Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6844 patients
Z Hang, Z Chao, LY Wang, XIE Hua, Z Jin… - Chinese medical …, 2013 - journals.lww.com
Background Gefitinib is widely used in patients with advanced non-small-cell lung cancer
(NSCLC), in whom chemotherapy had failed. Previous trials reported inconsistent findings …
(NSCLC), in whom chemotherapy had failed. Previous trials reported inconsistent findings …
Psychoonkologische Herausforderungen molekularer Therapien
F Schulz-Kindermann, H Schieder - Die Onkologie, 2016 - search.proquest.com
Hintergrund Molekulare onkologische Therapien zählen zu den sog.„personalisierten
“,„zielgerichteten “oder „individualisierten “Therapien. Während ihr therapeutischer Nutzen …
“,„zielgerichteten “oder „individualisierten “Therapien. Während ihr therapeutischer Nutzen …
Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs in Lung Adenocarcinoma Patients with EGFR Gene Mutations.
ZHU Xiang, L Liang, LIU Chen… - Chinese Journal of …, 2014 - search.ebscohost.com
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
have become first-line treatment drugs for lung adenocarcinoma patients with EGFR gene …
have become first-line treatment drugs for lung adenocarcinoma patients with EGFR gene …
Subtyping of nonsmall cell lung cancer on cytology specimens: reproducibility of cytopathologic diagnoses on sparse material
SH Omland, H Henrik, EK Olsen, T Birthe… - Diagnostic …, 2014 - Wiley Online Library
Cytologic examination of fine‐needle aspiration (material is increasingly used in diagnosing
lung cancer. High interobserver agreement in distinguishing small‐cell lung cancer from …
lung cancer. High interobserver agreement in distinguishing small‐cell lung cancer from …